Navigation Links
Antioxidant protects against lung damage in silicosis

Levels of heme oxygenase-1 (HO-1), an antioxidant that protects against reactive oxygen species (damaging oxygen molecules that cause direct tissue injury), become elevated in the lungs of chronic silicosis patients and could represent a new treatment approach for the disease.

These results appear in the second issue for October 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Yoshiaki Ishigatsubo, M.D., Ph.D., of the Department of Internal Medicine and Clinical Immunology at Yokohama City University in Japan, and 11 associates studied 46 male patients with silicosis, an inflammatory disorder caused by inhaling crystalline silica for prolonged periods. The study included 27 male patients with chronic obstructive pulmonary disease and 27 healthy male volunteers as controls. The investigators also studied a mouse model of silicosis.

Silicosis results from exposure to crystalline silica in mines and foundries, at sand blasting operations and at stone, clay, and glass manufacturing plants. Crystalline silica induces the production of reactive oxygen species, which can cause scar tissue to develop in the lungs.

About 1 million workers are believed to have been exposed to silica dust in the U.S. More than 10,000 silicosis patients are currently being followed in Japan.

"Pulmonary HO-1 expression is increased in silicosis," said Dr. Ishigatsubo. "HO-1 suppresses reactive oxygen species activity, and its subsequent pathologic changes, thereby reducing disease progression."

The researchers noted that their work was the first to demonstrate that HO-1 is synthesized in the lungs of patients with silicosis, thus contributing to a significant elevation of serum HO-1 levels in these patients.

"Silica particles were consistently associated with lesions containing HO-1 expressing cells," added Dr. Ishigatsubo. "The number of HO-1-expressing cells w as significantly higher in patients with silicosis than in control subjects."

The investigators said that their present results indicate that silicosis patients' serum HO-1 levels correlate significantly with their primary lung function test level and vital capacity. (Vital capacity is the maximum amount of air that can be exhaled after a maximum inhalation, showing the status of lung tissue.)

The authors believe that if serum HO-1 derives primarily from lung lesions, it could also represent a novel biomarker for evaluating the severity of silicosis.

In their mouse studies, hemin, a potent inducer of HO-1, suppressed acute inflammation after silica exposure, whereas zinc protoporphyrin, an inhibitor of HO-1, accelerated the development of silicosis lesions.
'"/>

Source:American Thoracic Society


Related biology news :

1. Antioxidant selenium offers no heart-disease protection
2. Bound for destruction: Ubiquitination protects against improper Notch signaling
3. Experiments provide proof of how traveling in groups protects insects
4. Experiments provide proof of how traveling in groups protects insects
5. Substance protects resilient staph bacteria
6. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
7. NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses
8. Mutation in clams protects against paralytic shellfish poisoning but raises human health risk
9. Excess liver gene protects against high-fat diet
10. New vaccine protects more effectively against tuberculosis
11. New type of rejection blocker protects kidneys after transplant

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... in medical device compliance and commercialization, has just released version 9.0 of the ... into this latest version of Cockpit,” says David Cronin, CEO of Cognition. “We’re ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY AMERICA, a ... food and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new ... The improvement in technology comes on the heels of HOLLOWAY’s release of the ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... example, are more likely to develop Alzheimer’s disease, while men are at greater ... for this gender-specific neuronal bias is the aim of a research program at ...
Breaking Biology Technology: